Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes
Hongyan Liu(University of Toronto), David Z.I. Cherney(University Health Network), Leif E. Lovblom(University of Toronto), Patrick R. Lawler(McGill University Health Centre), Hongping Ye(The University of Texas at San Antonio Health Science Center), Vikas S. Sridhar(University Health Network), Daniel Montemayor(The University of Texas at San Antonio Health Science Center), Yuliya Lytvyn(University Health Network), Kumar Sharma(The University of Texas at San Antonio Health Science Center), Jiwan Kim(The University of Texas at San Antonio Health Science Center), Bruce A. Perkins(Sinai Health System), Mir Tariq Ali(The University of Texas at San Antonio Health Science Center), Daniel Scarr(Mount Sinai Hospital)
Cited by 32
Related Papers
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight
|Science|2019|1.1k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
|JAMA|2020|884
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
|Bristol Research (University of Bristol)|2021|589
Metabolomics Reveals Signature of Mitochondrial Dysfunction in Diabetic Kidney Disease
|Journal of the American Society of Nephrology|2013|578